Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-117P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family[4][5]. The canonical U6 snRNA is a non-coding RNA component of the U6 snRNP (small nuclear ribonucleoprotein), an essential element of the spliceosome which catalyzes intron removal from pre-mRNA in eukaryotic cells[3]. The U6 snRNA sequence is highly conserved and found in multiple copies (including many pseudogenes) throughout vertebrate genomes, reflecting its evolutionary significance[3][4]. However, as a pseudogene, RNU6-117P does not encode a functional RNA product and is not transcribed or involved in splicing or other cellular processes[4]. Pseudogenes like RNU6-117P are sometimes used as genomic markers to study retrotransposition dynamics but are considered nonfunctional[5]. No drugs are known to interact with RNU6-117P, and it does not represent a druggable molecular target, a disease biomarker, or a therapeutic safety concern. In summary, RNU6-117P is a nonfunctional, processed pseudogene that arose from retrotranspositional mechanisms and sequence duplication involving the highly conserved U6 snRNA gene[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 117, pseudogene (RNU6-117P).